NSE · TORNTPHARM
Torrent Pharmaceuticals Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹4,145 Cr with net profit ₹498 Cr — a 12.01% net margin, versus 11.83% the period before.
Shareholding
As of 2026-09-30
- Promoter60.78%
- Public8.54%
- FII17.22%
- DII13.46%
1,42,140 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.49× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #1 of 51 by market cap · medians across 43 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited(this company) | ₹1,73,067 Cr | 77.57 | 20.58 | 11.42% | 12.27% |
| Gland Pharma Limited | ₹46,927 Cr | 40.95 | 4.53 | 9.92% | 16.78% |
| Ajanta Pharma Limited | ₹42,249 Cr | 37.23 | 9.33 | 23.33% | 19.65% |
| Rubicon Research Limited | ₹24,669 Cr | 85.6 | 19.14 | 19.14% | 14.89% |
| Shilpa Medicare Ltd. | ₹17,618 Cr | 61.95 | 6.8 | 9.39% | 17.67% |
| Caplin Point Laboratories Ltd. | ₹17,284 Cr | 25.98 | 5.13 | 17.88% | 29.09% |
| Eris Lifesciences Limited | ₹15,333 Cr | 23.35 | 3.93 | 15.87% | 20.04% |
| Marksans Pharma Limited | ₹13,443 Cr | 26.02 | 4.45 | 13.82% | 16.29% |
| Bliss GVS Pharma Ltd. | ₹6,596 Cr | 47.92 | 5.53 | 10.82% | 13.55% |
| Senores Pharmaceuticals Limited | ₹5,736 Cr | 45.39 | 6.14 | 12.36% | 18.59% |
AI analysis
AI-generated · google/gemini-2.5-flashTorrent Pharmaceuticals Limited is listed with a market capitalization of Rs 169405 Cr. The company reported revenue of Rs 13886.15 Cr and a profit margin of 15.55%. Its earnings per share (EPS) currently stand at Rs 64.76.
Positives
- +Revenue grew 21.4% to Rs 13886.15 Cr.
- +The return on equity (ROE) is 25.49%.
- +Promoter holding is 60.7794% as of July 31, 2026.
Negatives
- −The number of shareholders increased from 36530 in September 2019 to 140599 in July 2026, indicating increased dispersion.
- −Promoter pledge data is unavailable for periods prior to July 31, 2026, except for September 2019, which showed 36.49%.
Financial performance
For the period ending March 2026, Torrent Pharmaceuticals Limited recorded revenue of Rs 13886.15 Cr, showing a revenue growth of 21.4%. The company's net profit for the same period was Rs 2163.37 Cr. The latest quarterly revenue for March 2026 was Rs 4197 Cr, with a net profit of Rs 364 Cr.
Profitability & returns
The company's profit margin was 15.55%. Return on equity (ROE) was 25.49%, while return on capital employed (ROCE) stood at 13.8466%. The earnings per share (EPS) for the latest period was Rs 64.76.
Balance sheet
Torrent Pharmaceuticals Limited has a debt-to-equity ratio of 1.14. The book value per share is Rs 247.85. No data on pledged shares by promoters was available for the recent periods.
Ownership & pledges
As of July 31, 2026, promoter holding was 60.7794%. FIIs held 17.9709%, and DIIs held 12.8674%. The public shareholding was 8.38229999999999%. The number of shareholders was 140599. There were no reported promoter pledges.
Regulatory & surveillance
No information regarding surveillance measures for Torrent Pharmaceuticals Limited was available in the provided data.
Data as of — price: 2026-10-26 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Torrent Pharmaceuticals Limitedshare price & fundamentals